Premium
Diagnostic and prognostic significance of myelomonocytic cell surface antigens in acute myeloid leukaemia
Author(s) -
MerleBeral Félène,
Cong Duc Laurent Nguyen,
Leblond Véronique,
Boucheix Claude,
Michel Ariane,
Chastang Claude,
Debre Patrice
Publication year - 1989
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1989.tb07747.x
Subject(s) - immunophenotyping , antigen , myeloid , cd34 , cd33 , epitope , myeloid leukaemia , immunology , monoclonal antibody , cluster of differentiation , myelodysplastic syndromes , medicine , biology , antibody , stem cell , bone marrow , cell , genetics
Summary Thirty‐six cases of acute myeloid leukaemia (AML) were tested with a large battery of monoclonal antibodies (moAbs) detecting surface markers normally expressed by myelomonocytic, T and B lymphoid, megakaryocytic and erythroid lineages. Differences in antigenic expression were observed among the various FAB subgroups: HLA‐class II molecules were found in almost all AML cases but not in the promyelocytic subgroup (M3); CD14 and CD36 antigens were detected in monocytic leukaemias (M4 and M5); the CD34 moAb (MY10) recognizing an epitope described on myeloid stem cells was positive in 88% of the M1 and 80% of the M3 cases. By a multivariate analysis, only the CD14b (MY4) discriminated significantly between M1–M2 and M4–M5 subgroups. Using Cox's model to assess the prognostic importance of variables including immunophenotyping on survival, we undertook a one by one analysis and found that the presence of CD17 antigen predicted for a shorter survival ( P = 0.03). In addition this marker appeared more significant than other clinical and biological parameters.